The Contingency of Reported sST2 Serum Concentrations with a Protein Detection System (ELISA) from the Same Manufacturer (R&D Biotechne, 2002-2025): An Explanatory Effort by Applied Medical Researchers
- PMID: 41008783
- PMCID: PMC12468627
- DOI: 10.3390/diagnostics15182412
The Contingency of Reported sST2 Serum Concentrations with a Protein Detection System (ELISA) from the Same Manufacturer (R&D Biotechne, 2002-2025): An Explanatory Effort by Applied Medical Researchers
Abstract
Background/Objectives: Soluble ST2 (sST2) has gained recognition as a clinically relevant biomarker across a spectrum of inflammatory, cardiovascular, and respiratory conditions. However, the lack of assay standardization raises concerns about result comparability across platforms and studies. Methods: This study systematically evaluated serum sST2 concentrations measured with two ELISA systems-DuoSet and Quantikine-produced by the same manufacturer (R&D Systems, Minneapolis, MN, USA). Results: Using archived serum samples from healthy volunteers and marathon runners, we identified marked discrepancies: serum sST2 concentrations using the DuoSet recombinant standard were on average 4.3-fold higher than those using Quantikine (median 308.3 [106.6-608.6] vs. 71.5 [41.8-115.6] ng/mL). On the pre-coated Quantikine plate, using the DuoSet recombinant standard increased calculated concentrations 4.3-fold compared with the native Quantikine standard (median 308.3 [106.6-608.6] vs. 71.5 [41.8-115.6] ng/mL). On the manually coated DuoSet plate, the DuoSet standard yielded higher medians than the Quantikine standard (8.0 [5.6-11.3] vs. 5.0 [3.7-7.4] ng/mL). Furthermore, between-lot variability within the same ELISA platform resulted in concentration shifts from 0.09 [0.07-0.10] ng/mL (2016) to 1.17 [0.81-3.23] ng/mL (2023) using the same sample. Previously published studies also exhibited wide inter-study variability among healthy cohorts. Conclusions: These findings emphasize that current ELISA systems for sST2 are not standardized and that cross-study comparisons should be interpreted with caution. Until universal standardization is implemented, sST2 should primarily be used for within-study comparisons. This variability may limit the reliability of longitudinal sST2 assessment even in clinical settings.
Keywords: ELISA standardization; biomarker variability; sST2.
Conflict of interest statement
Authors Hannes Kühtreiber, Lisa Auer and Hendrik Jan Ankersmit were employed by the company Aposcience AG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- Meijers W.C., Bayes-Genis A., Mebazaa A., Bauersachs J., Cleland J.G.F., Coats A.J.S., Januzzi J.L., Maisel A.S., McDonald K., Mueller T., et al. Circulating heart failure biomarkers beyond natriuretic peptides: Review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC) Eur. J. Heart Fail. 2021;23:1610–1632. doi: 10.1002/ejhf.2346. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
